Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Keld Per Kjeldsen
Drug-drug interaction (DDI), defined as an interaction between two or more drugs, has been found to occur in up to 28 % of hospitalized patients. DDIs may be potentially or clinically relevant. Clinically harmful DDIs can occur with many cardiovascular drugs, e.g. lipid lowering agents (rhabdomyolysis), anticoagulants (bleeding), antiplatelets (bleeding) and antiarrhythmic agents (sudden cardiac death).The number of interactions that the cardiologist should be aware of is rapidly expanding with the development of new drugs. The cardiologist must be aware of interactions among cardiovascular drugs. Also, since many patients are in pharmacotherapy also for non-cardiovascular diseases, the cardiologist should keep in mind potential interactions among cardiovascular and non-cardiovascular drugs, as well as interactions among non-cardiovascular drugs.It was underlined that there is a need for computerized systems that check prescriptions for harmful interactions. At present, such systems are only rarely available to cardiologists working in hospitals or in private practice in Europe. The suggestion was that ESC might consider providing the information on harmful interactions needed, to partner in developing such a computer system and make it available to European cardiologists maybe on an EU-funded basis.
Drug interactions: what the cardiologist should know